Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Organisation › Details

Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools – meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors. To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending. Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over €70 million in funding since inception. *

 

Period Start 1999-01-01 established
  Group Cellectis (Group)
Products Industry genome editing (gene editing)
  Industry 2 TALEN (Transcription Activator-Like Effector Nuclease)
Persons Person Choulika, André (Cellectis 200701 CEO + co-founder)
  Person 2 Dutang, Eric (Cellectis 2016– CFO joined 201505)
     
Region Region Romainville
  Country France
  Street 8 Rue de la Croix Jarry
  City 75013 Paris
  Tel +33-1-8169-1600
    Address record changed: 2015-04-24
     
Basic data Employees D: 101 to 500 (2016-12-31)
  Currency USD
  Annual sales 21,432,000 (income, total, consolidated (2018) 2018-12-31)
  Profit -88,333,000 (2018-12-31)
  Cash 451,501,000 (2018-12-31)
     
    * Document for �About Section�: Cellectis S.A.. (1/20/11). "Press Release: Cellectis Acquires Exclusive License to TAL Effector Patents from University of Minnesota". Paris.
     
   
Record changed: 2019-11-03

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Cellectis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top